Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). Materials and Methods From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated. Results A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression- free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively. Conclusion After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy of radiation dose to the tumor regression field may be feasible and need further investigation.
Abstract
Purpose This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). Materials and Methods From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated. Results A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression- free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively. Conclusion After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy of radiation dose to the tumor regression field may be feasible and need further investigation.
참고문헌 (28)
- Razak AR, "Nasopharyngeal carcinoma : the next challenges", Eur J Cancer, 46, pp.1967~1978 (2010)
- Pfister DG, "NCCN clinical practice guidelines in oncology (NCCN Guidelines): head and neck cancers. Version 2.2016-October 11, 2016", National Comprehensive Cancer Network, ~ (2016)
- Sun Y, "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma : a phase 3, multicentre, randomised controlled trial", Lancet Oncol, 17, pp.1509~1520 (2016)
- Hui EP, "Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma", J Clin Oncol, 27, pp.242~249 (2009)
- Fountzilas G, "Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation", Ann Oncol, 23, pp.427~435 (2012)
- Ma J, "Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma", J Clin Oncol, 19, pp.1350~1357 (2001)
- Halperin EC, "Perez and Brady’s principles and practice of radiation oncology", pp.203~268 (2013), Lippincott Williams &Wilkins
- Salama JK, "Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer", Int J Radiat Oncol Biol Phys, 75, pp.725~733 (2009)
- Illidge T, "Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group", Int J Radiat Oncol Biol Phys, 89, pp.49~58 (2014)
- Kalemkerian GP, "NCCN clinical practice guidelines in oncology (NCCN guidelines): small cell lung cancer. Version 3.2017-February 23, 2017", National Comprehensive Cancer Network, ~ (2017)
- De Ruysscher D, "European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer", J Clin Oncol, 28, pp.5301~5310 (2010)
- Sun Y, "Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensitymodulated radiotherapy", Radiother Oncol, 110, pp.390~397 (2014)
- Sun Y, "Reduction of clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensity-modulated radiotherapy", Head Neck, 38(Suppl 1), pp.E468~E472 (2016)
- Xiao WW, "Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy : long-term results of a phase 2 study", Cancer, 117, pp.1874~1883 (2011)
- "RTOG 0225 protocol information" (2008)[URL]
- Kong F, "Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma", Radiat Oncol, 9, pp.60~ (2014)
- Fletcher GH, "Clinical dose response curves of human malignant epithelial tumours", Br J Radiol, 46, pp.151~ (1973)
- Tang LQ, "Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma : an openlabel, non-inferiority, randomised phase 3 trial", Lancet Oncol, 19, pp.461~473 (2018)
- Girinsky T, "Involved-node radiotherapy(INRT)in patients with early Hodgkin lymphoma : concepts and guidelines", Radiother Oncol, 79, pp.270~277 (2006)
- Verhappen MH, "Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma", Radiother Oncol, 109, pp.133~139 (2013)
- Girinsky T, "The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines", Radiother Oncol, 88, pp.202~210 (2008)
- Maraldo MV, "Involved node radiation therapy : an effective alternative in early-stage hodgkin lymphoma", Int J Radiat Oncol Biol Phys, 85, pp.1057~1065 (2013)
- De Ruysscher D, "European Organization for Research and Treatment of Cancer(EORTC)recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer", Radiother Oncol, 124, pp.1~10 (2017)
- Yu Z, "Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma", Ai Zheng, 28, pp.1132~1137 (2009)
- Xue F, "Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma", Onco Targets Ther, 10, pp.3329~3336 (2017)
- Yang H, "Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma : a prospective, multi-center, randomized clinical trial", Radiother Oncol, 126, pp.37~42 (2018)
- Zhou GQ, "Radiation-induced temporal lobe injury for nasopharyngeal carcinoma:a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy", PLoS One, 8, pp.e67488~ (2013)
- Su SF, "Analysis of dosimetric factors associated with temporal lobe necrosis(TLN)in patients with nasopharyngeal carcinoma(NPC)after intensity modulated radiotherapy", Radiat Oncol, 8, pp.17~ (2013)